NCT06245837View on ClinicalTrials.gov

Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

Active, not recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Non-small-cell Lung Cancer
Trial Locations (16)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Irkutsk

Research Site, Kemerovo

Research Site, Kostroma

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Novokuznetsk

Research Site, Novosibirsk

Research Site, Obninsk

Research Site, Perm

Research Site, Saint Petersburg

Research Site, Ufa

Research Site, Vladivostok

Research Site, Yaroslavl

Research Site, Yekaterinburg

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT06245837 - Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations | Biotech Hunter | Biotech Hunter